100 related articles for article (PubMed ID: 8558502)
1. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase.
Hunt JT; Lee VG; Leftheris K; Seizinger B; Carboni J; Mabus J; Ricca C; Yan N; Manne V
J Med Chem; 1996 Jan; 39(2):353-8. PubMed ID: 8558502
[TBL] [Abstract][Full Text] [Related]
2. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
3. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of farnesyltransferase and Ras processing peptidase.
Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
6. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
deSolms SJ; Giuliani EA; Graham SL; Koblan KS; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH; Wiscount CM; Gibbs JB; Smith RL
J Med Chem; 1998 Jul; 41(14):2651-6. PubMed ID: 9651171
[TBL] [Abstract][Full Text] [Related]
7. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
[TBL] [Abstract][Full Text] [Related]
8. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
9. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
[TBL] [Abstract][Full Text] [Related]
10. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
[No Abstract] [Full Text] [Related]
11. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
Sakowski J; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
[TBL] [Abstract][Full Text] [Related]
12. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
[No Abstract] [Full Text] [Related]
13. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.
Goldstein JL; Brown MS; Stradley SJ; Reiss Y; Gierasch LM
J Biol Chem; 1991 Aug; 266(24):15575-8. PubMed ID: 1874715
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.
Li Q; Woods KW; Wang W; Lin NH; Claiborne A; Gu WZ; Cohen J; Stoll VS; Hutchins C; Frost D; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2005 Apr; 15(8):2033-9. PubMed ID: 15808463
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold.
Ohkanda J; Lockman JW; Kothare MA; Qian Y; Blaskovich MA; Sebti SM; Hamilton AD
J Med Chem; 2002 Jan; 45(1):177-88. PubMed ID: 11754590
[TBL] [Abstract][Full Text] [Related]
17. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
Kettler K; Wiesner J; Silber K; Haebel P; Ortmann R; Sattler I; Dahse HM; Jomaa H; Klebe G; Schlitzer M
Eur J Med Chem; 2005 Jan; 40(1):93-101. PubMed ID: 15642414
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
[No Abstract] [Full Text] [Related]
19. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
20. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
